Cancers
Machine Learning-Guided Virtual Screening Identifies a Novel MELK-Targeted Antiproliferative Lead Compound with G2/M Arrest Activity in Triple-Negative Breast Cancer and Lung Adenocarcinoma Cells
Par Cao W, Jiang B, Chi X et 9 autres.
Contenu en anglais
Résumé
Background
Maternal embryonic leucine zipper kinase (MELK) is a cell cycle-regulated serine/threonine kinase frequently overexpressed in human malignancies, and represents a promising anticancer drug target. Discovery of structurally novel, highly selective MELK inhibitors remains an unmet need.